Capricor Therapeutics Inc (NASDAQ: CAPR) kicked off on Monday, down -3.41% from the previous trading day, before settling in for the closing price of $10.25. Over the past 52 weeks, CAPR has traded in a range of $3.52-$23.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 11.01%. While this was happening, its average annual earnings per share was recorded 90.09%. With a float of $40.15 million, this company’s outstanding shares have now reached $45.68 million.
Considering the fact that the conglomerate employs 160 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 100.0%, operating margin of -329.9%, and the pretax margin is -317.13%.
Capricor Therapeutics Inc (CAPR) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Capricor Therapeutics Inc is 12.16%, while institutional ownership is 40.24%. The most recent insider transaction that took place on Sep 20 ’24, was worth 14,999,998. In this transaction 10% Owner of this company bought 2,798,507 shares at a rate of $5.36, taking the stock ownership to the 7,090,351 shares.
Capricor Therapeutics Inc (CAPR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 90.09% per share during the next fiscal year.
Capricor Therapeutics Inc (NASDAQ: CAPR) Trading Performance Indicators
Take a look at Capricor Therapeutics Inc’s (CAPR) current performance indicators. Last quarter, stock had a quick ratio of 6.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.42, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of Capricor Therapeutics Inc (CAPR)
Compared to the last year’s volume of 1.9 million, its volume of 1.25 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 66.04%.
During the past 100 days, Capricor Therapeutics Inc’s (CAPR) raw stochastic average was set at 36.84%, which indicates a significant decrease from 51.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 193.67% in the past 14 days, which was higher than the 139.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.65, while its 200-day Moving Average is $13.65. Nevertheless, the first resistance level for the watch stands at $10.12 in the near term. At $10.34, the stock is likely to face the second major resistance level. The third major resistance level sits at $10.57. If the price goes on to break the first support level at $9.66, it is likely to go to the next support level at $9.43. Should the price break the second support level, the third support level stands at $9.21.
Capricor Therapeutics Inc (NASDAQ: CAPR) Key Stats
The company with the Market Capitalisation of 452.51 million has total of 45,677K Shares Outstanding. Its annual sales at the moment are 22,270 K in contrast with the sum of -40,470 K annual income. Company’s last quarter sales were recorded 11,130 K and last quarter income was -7,120 K.
